- Podcast
- 18/03/2021
- UK
VTE: From Tomb Dust to Aspirin via Heparin
Description
This month's Bone & Joint 360 Podcast hosted by Tim Coughlin delves into the critical topic of venous thromboembolism (VTE), with a focus on its prevalence, risk factors, and historical treatment advancements. The podcast features a discussion on deep vein thrombosis (DVT) and its historical cases dating back to the 13th century, alongside insights into modern thromboprophylaxis strategies. Coughlin explores how thromboprophylaxis has evolved from the use of heparin in the early 20th century to contemporary novel oral anticoagulants (NOACs) such as dabigatran and rivaroxaban.
Listeners learn about the significant risks associated with DVT, especially in surgical patients, and hear from renowned surgeons, including Dr. William Geerts, who discusses clinical definitions of important venous thromboembolism outcomes and the effectiveness of prophylaxis protocols in trauma settings. The conversation shifts to practical implications within virtual fracture clinics, showcasing the integration of factoring in DVT risk for patients treated outside traditional hospital settings.
The narrative continues into elective surgeries, featuring Dr. John Murnaghan, who addresses pivotal research on aspirin versus rivaroxaban for VTE prophylaxis in hip and knee arthroplasties. The podcast concludes with reflections on the future of thromboprophylaxis research, shedding light on the nuances of managing bleeding risks in patients receiving anticoagulants. This informative episode rounds out with insights and takeaways that promise to enrich understanding and clinical practices surrounding thromboembolic events.